Livagen
Lys-Glu-Asp-Ala (liver)
Livagen is Lys-Glu-Asp-Ala, aimed at the liver. It has one thing almost nothing else in this cohort has — a paper on human cells from named elderly donors — and one thing it shares with all of them: no clinical endpoint anywhere.
Livagen quick facts
| Reported research dose | 2mg-5mg (per course) |
| Route | Subq |
| Frequency | 1x Daily · Daily (course) |
| Half-life | ~30 min |
| Forms | Injectable |
| Evidence level | Russian studies; limited |
Liver-focused bioregulator — course-based support. Liver-focused, and close enough to Svetinorm that running both is duplication. Course pattern: roughly 10 days on, then off, once or twice a year. To know whether it did anything, ALT, AST and GGT on a CMP, before and at 3 months. Run it as an experiment you measure, not a protocol you trust.
How Livagen works — what 4 residues can and cannot do
Livagen is Lys-Glu-Asp-Ala — a tetrapeptide, molecular weight 461.5 g/mol, isoelectric point 4.18, net charge about -1.1 at blood pH. Those four numbers are computed from the sequence, not quoted from a vendor.
Lys-Glu-Asp-Ala. Four residues — Vesugen's tripeptide with an alanine added — and the only compound in this family whose headline claim was measured in human cells rather than modeled on a computer.
What was actually observed. Khavinson et al. treated lymphocytes taken from old people and reported that Livagen induced activation of ribosomal genes, decondensation of pericentromeric structural heterochromatin, and release of genes repressed by age- related condensation of euchromatic regions. That is a chromatin- structure result in primary human cells, and it is a different kind of evidence from a docking score. It is also the mechanism this whole class is supposed to have, observed once, in a dish, in 2002 — and never followed up.
Why chromatin decondensation is a better story than DNA recognition. A four-residue peptide cannot read a promoter address: a zinc finger uses about 30 amino acids to read three base pairs, and even a nine-base site occurs tens of thousands of times in a 3.1-billion-base genome. But loosening condensed heterochromatin does not require sequence recognition at all — it requires charge interaction with the DNA backbone and the histones packing it. That is chemistry a small charged peptide could plausibly do, and it is the version of the mechanism that survives scrutiny. It is also non-specific by construction, which is the honest cost: a molecule that decondenses chromatin has no way of choosing which genes it releases.
The charge point. Lysine's positive charge against two acidic residues leaves Livagen near −1 at blood pH — less repelled by a polyanionic backbone than the doubly acidic peptides on neighboring pages, and carrying the one positive side chain that could contact phosphate. For a chromatin-loosening mechanism that is the right chemistry. For a sequence-recognition mechanism it is nowhere near enough.
Lys-Glu-Asp-Ala. Four residues — which puts it outside the di/tripeptide substrate range the intestinal transporter review describes, and that has consequences for any oral form.
What the primary literature on Livagen actually says
Effects of Livagen Peptide on Chromatin Activation in Lymphocytes from Old People
Khavinson VKh, Lezhava TA, Monaselidze JG, Dzhokhadze TA, Dvalishvili NA, Bablishvili NK, Ryadnova IYu · Bulletin of Experimental Biology and Medicine 2002;134(4):389–392 · PMID 12533768
Human lymphocytes from old people. Livagen is reported to activate ribosomal genes, decondense pericentromeric structural heterochromatin, and release genes repressed by age-related condensation of euchromatic regions. This is the chromatin-decondensation claim in its original form. The abstract reports direction only — no donor count, no ages, no effect size — and those numbers sit behind a paywall in Bulletin of Experimental Biology and Medicine.
Peptide Regulation of Gene Expression: A Systematic Review
Khavinson VKh, Popovich IG, Linkova NS, Mironova ES, Ilina AR · Molecules 2021;26(22):7053 · PMID 34834147
Sets out the general claim that peptides of two to seven residues reach the nucleus and interact with nucleosomes and histones — the mechanism the chromatin result would be evidence for.
Transport of Biologically Active Ultrashort Peptides Using POT and LAT Carriers
Khavinson V, Linkova N, Kozhevnikova E, Dyatlova A, Petukhov M · International Journal of Molecular Sciences 2022;23(14):7733 · PMID 35887081
Relevant for a distinction the review makes and almost nobody repeats. PEPT1 — the transporter on the brush border of the small intestine, the one that would have to carry a swallowed peptide — is described as handling “basically all di- and tripeptides”. PEPT2, which does take “di-, tri- and tetrapeptides (preferably dipeptides)”, sits mainly in the kidney and is not the absorption route. Livagen has four residues. So the transporter argument that makes an oral tripeptide arguable is weaker for this compound than for its shorter siblings, and the reason is a specific sentence in a specific paper rather than a hunch.
What is not here. Nothing is indexed under the trade name Livagen; the peptide itself has one human-cell paper under its own name. Searched through Europe PMC, PubMed and Google Scholar on 2 September 2026. Naming the gap is more useful than filling it with a paragraph of hedging.
Why the Livagen evidence is weak — and what it still showed
Almost every human result in this class comes from one school — Vladimir Khavinson's institute in St Petersburg and the groups around it. That means single-center data, collected by the people who developed the compound, rarely blinded, never pre-registered, and reported across enough endpoints that something was always going to move. Read anything below against that.
Specific to Livagen. Chromatin decondensation in donor lymphocytes is a real measurement and it is also a long way from a liver claim. The cells are blood cells, not hepatocytes; the endpoint is chromatin structure, not liver function; and the study is descriptive rather than controlled. Nothing published attaches Livagen to a liver enzyme, a fibrosis score, or an imaging endpoint in any species.
What the data does support. One peer-reviewed experiment in primary human lymphocytes from elderly donors, reporting activation of ribosomal genes and decondensation of pericentromeric heterochromatin. Published in Bulletin of Experimental Biology and Medicine in 2002, PMID 12533768. It is a real result in human cells and it is the single most mechanism-relevant observation anywhere in this catalog.
What it does not support. The abstract gives direction only — no donor count, no ages, no effect size, no control description beyond the comparison implied. Those numbers sit behind a paywall, and this page will not guess them. Nothing has replicated it in the twenty-four years since, by this group or any other. And the study says nothing about the liver, which is the organ the trade name is sold against: the peptide's one human result is about lymphocyte chromatin, not hepatic anything.
The specific epistemic position: one unreplicated positive result in human cells, in a tissue unrelated to the marketed indication, with the effect size unavailable. That is thin — and it is still more than most compounds here have.
What is actually measured, and what is not. Measured once, in 2002, in primary human lymphocytes: ribosomal gene activation and decondensation of pericentromeric heterochromatin. Not measured even there: donor count, donor ages, effect size — the abstract gives direction only. Not measured anywhere: plasma half-life, clearance, nuclear uptake, any hepatic endpoint, and any replication of the 2002 result in the twenty-four years since.
Not proven is not the same as disproven. Everything above says the evidence is weak. None of it says the compound does nothing. There is no adequately powered trial that ran and came back null, because outside Russia there is essentially no trial at all — this class is unfunded, not failed. A reader who leaves thinking “disproven” has learned something false, and so has one who leaves thinking “proven”.
Livagen pharmacokinetics — how much of it actually gets in
What degrades it. Three peptide bonds, free N-terminal lysine, no protection. Aminopeptidases cleave from that terminus preferentially. The quick facts list “~30 min”, which has no traceable human study behind it.
The transporter distinction that applies specifically to this compound. The intestinal case for oral short peptides rests on PEPT1, on the brush-border membrane of the small intestine, whose substrate range the originating group's review describes as “basically all di- and tripeptides”. Livagen has four residues. Its sibling transporter PEPT2 does handle “di-, tri- and tetrapeptides (preferably dipeptides)” — but PEPT2 is expressed mainly in the kidney proximal tubule, not the gut wall. So the tetrapeptide is not excluded from transport in general; it is excluded from the specific transporter that would absorb it. That distinction is in the paper and essentially nobody repeats it.
The exposure bound. Livagen is sold injectable only, which sidesteps the question: an injection is 100% bioavailable by definition, with no gut wall and no hepatic first-pass to survive. The unmeasured step is the one after that — the chromatin result was produced by putting the peptide directly onto lymphocytes in culture, and no study has shown that an injected dose reaches circulating lymphocytes at a comparable concentration. Between the dish and the human there is an entire pharmacokinetic argument that has never been made.
The ratio the catalog itself implies. Across this class, the oral products carry a median of roughly 29x more material per day than the injectable ones. Nobody arrived at that by measuring absorption — no oral bioavailability figure has been published for any compound in this family — but the gap is the vendors' own implicit answer to the question: swallowing it is assumed to deliver a small fraction of what an injection delivers, and an injection is fully bioavailable by definition. Treat that as a bound on the plausible exposure, not as a measurement, because a measurement is exactly what is missing.
What would have to be true for Livagen to work
What would have to be true. Lys-Glu-Asp-Ala would have to survive long enough after injection to reach cells at a concentration comparable to the culture experiment; enter those cells and their nuclei; and loosen condensed chromatin enough to change which genes are transcribed. The 2002 result supports the last step in a dish. The first two have never been examined, and the leap from a dish to a bloodstream is where most cell-culture pharmacology dies.
Because the marketed organ is the liver and the evidence is about lymphocytes, the honest test looks at both.
- Prediction 1 — GGT (Gamma-Glutamyl Transferase). should not rise; a fall in someone with a raised baseline would be the first real signal, over a course, with a repeat 4–6 weeks later. GGT is the most responsive of the routine liver enzymes and the one most likely to move if anything hepatic is happening.
- Prediction 2 — Complete Blood Count (CBC) with Differential. the lymphocyte line is the one to watch, because it is the only cell type this compound has ever been tested on, over a course, repeated 4–6 weeks later. Khavinson's 2002 result was chromatin decondensation in lymphocytes from elderly donors — not a hepatic finding at all. If the compound does anything in a human, the cell type it was actually studied in is the honest first place to look, and a differential is close to free.
- Prediction 3 — hs-CRP (High-Sensitivity C-Reactive Protein). no prediction — a rise would be a reason to stop. Named as a safety readout rather than an efficacy one.
Run these before and after, not after alone. A single post-course number tells you what your body is doing, not what Livagen did to it — and that difference is the entire point of testing.
Livagen versus the alternatives
Livagen versus Svetinorm. Svetinorm is the liver extract; Livagen is the defined tetrapeptide sold for the same organ. The extract cannot be chemically identified and has no indexed trial; the peptide has a verifiable mass and one human cell-culture paper about lymphocytes. Neither has liver evidence. That is the honest summary and it is not what either product's marketing says.
Livagen versus Vesugen is the more interesting comparison: KEDA is KED plus an alanine. If a single terminal residue redirects a peptide from blood vessels to liver, that is an extraordinary claim about tissue specificity and it has never been tested. If it does not, then two products sold for different organs are close analogs of one another with overlapping cell-culture profiles.
And against the credible alternative. For liver health the interventions with human outcome data are alcohol reduction, weight loss, treating viral hepatitis and managing metabolic syndrome. Every one of them moves GGT and liver fat with trial evidence behind it. A tetrapeptide with one lymphocyte-chromatin paper is not a comparison to them; it is a different category of thing entirely.
What you are actually buying when you buy Livagen
Defined tetrapeptide — one correct mass, confirmable by mass spectrometry, HPLC purity alongside.
The name-to-sequence mapping is the weak link, and it is weaker here than for its siblings. The one primary paper published under the name Livagen does not state a sequence in its abstract at all. So the identification of Livagen as Lys-Glu-Asp-Ala rests on vendor consensus, and the human result everyone cites for this compound is attached to a trade name rather than to a molecule. If the mapping is wrong, the citation does not transfer. This repo records the sequence as claimed rather than verified for exactly that reason.
Expect/mol. Four residues means four possible truncation products, each of which is a real peptide with its own mass — ask for the purity figure and the method, not just a percentage.
Where to get Livagen
Buy Livagen at Biolongevity Labs →Bacteriostatic water is the diluent — sterile water with 0.9% benzyl alcohol, which is what lets a vial be drawn from more than once. It does not come with the vial, and unlike the compound it is bought again every time.
Need bacteriostatic water? Get it at AminoWell USA (my company) → Code CAMERON.
The evidence for Livagen
Graded by what exists behind each claim.
Human clinical evidence
- The human record is Soviet and post-Soviet clinical work — real patients and real endpoints, published in Russian and rarely replicated to Western standards.
📊 Correlative data
- Used for liver support. The most interesting published item on it is not a liver finding — Khavinson's group reported chromatin decondensation in lymphocytes from elderly donors, which is one of the few cell-level results in the series that others could in principle repeat.
🧪 Theoretical / extrapolated
- Lys-Glu-Asp-Ala — a defined tetrapeptide targeting hepatic tissue.
- The shared claim across the Khavinson series: peptides this short are proposed to enter the cell nucleus and bind promoter regions of DNA, shifting tissue-specific gene expression.
- The chromatin work is where this hypothesis is most testable. Decondensation is measurable, and a replication attempt by any independent cytogenetics lab would settle a great deal about the whole series. That it has not happened in twenty years is itself informative.
What that tier rests on here. The tier above rests on one 2002 human cell-culture paper about lymphocyte chromatin — unreplicated since, and about a tissue other than the liver this compound is sold for.
How to read the Soviet clinical series → · The Khavinson series, in full →
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
Cell, rodent, human — and where it stops
Livagen has the deepest per-compound record of any defined peptide in this catalog, and almost none of it is about the liver. Lys-Glu-Asp-Ala, 461.5 g/mol, four residues — and the experiments that were actually run on it are chromatin experiments in lymphocytes.
In human cells. Khavinson 2002 reports chromatin activation in lymphocytes taken from old people. Lezhava 2007, in Annals of the New York Academy of Sciences, reports activation of pericentromeric and telomeric heterochromatin in cultured lymphocytes from old individuals; Lezhava 2023 is the same Georgian group two decades on. Dzhokhadze 2007 went further and used an actual challenge: the radiation-induced adaptive response in cells from elderly donors, with Livagen as the correcting agent. A radiation-response assay has a hard endpoint that is difficult to talk yourself into.
In human serum — the only measurement of its kind in this class. Kost 2003 assayed enkephalin-degrading enzyme activity in human serum under Livagen and Epitalon. It is not a clinical trial and it is not pharmacokinetics, but it is a peptide-in-human-plasma measurement, and this class has almost none.
In rats and in liver tissue. Riadnova 2002 is the organotypic liver culture study. Brodskii 2001 is the most unusual paper in the whole cohort: it measured the rhythm of protein synthesis in hepatocytes from rats of different ages, and asked what Livagen did to it. Timofeeva 2005 measured digestive-enzyme activities along the gastrointestinal tract and in non-digestive organs in rats of different ages.
Where it stops. Not one of those is a human liver endpoint. There is no trial, no liver function panel, no imaging, no histology in a person. The tissue on the label is the one tissue this compound has never been tested in.
What nobody has tested yet
The liver has the cheapest endpoint in medicine and this compound has never been put through it. ALT, AST, GGT and bilirubin cost almost nothing, are on every routine panel, and move measurably in real liver disease. A product named for the liver, with twenty years of chromatin papers behind it and zero published liver enzyme values, has not been tested against the obvious.
Brodskii's rhythm experiment is the one worth repeating. Protein synthesis in hepatocyte culture oscillates, the oscillation changes with donor age, and a compound that restores it would be showing something no blood test could. The assay is twenty-five years old and has never been reproduced by a second laboratory, on this or any peptide.
Extrapolation, labeled as such. If Livagen really acts on chromatin in lymphocytes, the read-out that would show it in a living person is not a liver panel at all — it is an epigenetic clock from whole blood, which is exactly the tissue every one of these papers used. Methylation clocks are commercially available and reasonably cheap. No peptide in this class has ever been run against one, and this is the compound with the most reason to try.
Sources read for this page
- Khavinson VKh, Lezhava TA, Monaselidze JG, Dzhokhadze TA, Dvalishvili NA, Bablishvili NK, Ryadnova IYu. Effects of Livagen Peptide on Chromatin Activation in Lymphocytes from Old People. Bulletin of Experimental Biology and Medicine 2002;134(4):389–392 · PMID 12533768
- Riadnova IIu, Filippov SV, Iuzhakov VV. Functional morphology of an organotypic liver culture exposed to the peptide livagen. Advances in Gerontology 2002 [Russian] · PMID 12577697
- Brodskii VIa, Khavinson VKh, Zolotarev IuA, Nechaeva NV, Malinin VV, Novikova TE, Gvazava IG, Fateeva VI. Rhythm of protein synthesis in cultures of hepatocytes from rats of different ages. Norm and effect of the peptide livagen. Izvestiia Akademii Nauk Seriia Biologicheskaia 2001 [Russian] · PMID 15926314
- Timofeeva NM, Khavinson VKh, Malinin VV, Nikitina AA, Egorova VV. Effect of peptide Livagen on activity of digestive enzymes in gastrointestinal tract and non-digestive organs in rats of different ages. Advances in Gerontology 2005 [Russian] · PMID 16075683
- Kost NV, Sokolov OIu, Gabaeva MV, Zolotarev IuA, Malinin VV, Khavinson VKh. Effect of new peptide bioregulators livagen and epitalon on enkephalin-degrading enzymes in human serum. Izvestiia Akademii Nauk Seriia Biologicheskaia 2003 [Russian] · PMID 12942748
- Dzhokhadze TA, Buadze TZh, Dvalishvili NA, Lezhava TA. Variability of radiation-induced adaptive response in old age individuals and their correction by peptide bioregulator Livagen. Georgian Medical News 2007 · PMID 17921545
- Lezhava T, Jokhadze T. Activation of pericentromeric and telomeric heterochromatin in cultured lymphocytes from old individuals. Annals of the New York Academy of Sciences 2007 · PMID 17460203
- Lezhava T. Epigenetic modification under the influence of peptide bioregulators on the old chromatin. Georgian Medical News 2023 · PMID 37042594
Livagen — safety, predicted from mechanism
Predicted from mechanism, not from a human safety trial. How that reasoning works →
What the mechanism predicts
Derived from the molecule, not a trial.
- These are short peptide fragments of organ extracts, and the honest starting point is that the mechanism itself is not established in a way that lets anyone predict harm precisely. The proposal is gene-regulatory — short peptides binding DNA and modulating transcription in a tissue-specific way. If that is what they do, the theoretical concern is influencing transcription in tissue you were not aiming at.
- In practice the doses are tiny, the peptides are short, and they are degraded quickly — which is also the argument that they may do very little at all. Those two possibilities are the same uncertainty viewed from opposite ends, and you should hold both.
What has actually been reported
- Decades of Russian clinical use with a strikingly clean tolerability record — injection-site reactions and little else reported.
- That record comes almost entirely from one research school, is largely unreplicated outside it, and safety data from a group with an interest in the outcome is worth less than the same data from a skeptic. This is not an accusation; it is how evidence weighting works.
How to reduce the risk
Same mechanism as the prediction.
- Follow the course printed on the label rather than running continuously. These are the one class in the Vault where a duration is STATED rather than inferred, and it is typically 10–20 days repeated a few times a year. Read the box.
- Run one at a time. They are cheap and it is tempting to stack six. If something changes, a stack of six tells you nothing about which one did it — and given the evidence base, attribution is the entire value of your own experiment.
- Decide your endpoint before you start, and make it a marker or a measurable symptom rather than a feeling. With a compound class this under-evidenced, an unfalsifiable endpoint means you will conclude it worked no matter what happened.
- Buy from a source that publishes third-party testing. Where the molecule itself is uncertain, identity and purity are the only variables you can actually control.
What it does to your bloodwork
A fact about the assay.
- Test the ORGAN, not the peptide. A thymic peptide is judged on immune markers, a pineal one on sleep and IGF-1, a vascular one on lipids and inflammatory markers. There is no assay for the compound itself.
Don't run this if
- Pregnancy — not because of a specific finding, but because nobody has studied it and the mechanism claim is transcriptional.
- Active malignancy, on the same reasoning as any tissue-growth signal: unproven, mechanistically arguable, and not worth finding out.
The honest unknown
- Essentially everything a skeptic would want: independent replication, pharmacokinetics, and whether the oral forms survive digestion at all. Unproven is not the same as ineffective — but here it is a large unproven.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
Livagen — safety specifics for this compound
Specific to Livagen: the proposed mechanism is chromatin decondensation, and that is the one mechanism in this catalog with an obvious theoretical downside — releasing genes that age-related condensation had silenced is only good if you like what gets released. Nothing in the literature has examined that, in any system, over any timescale. It is not a reported harm and should not be read as one; it is a named, specific unknown that follows directly from the mechanism the product is sold on. The evidence base is one experiment — primary human lymphocytes from elderly donors, Bulletin of Experimental Biology and Medicine 2002, PMID 12533768 — and n=1 study is not a safety record. Decondensing pericentromeric heterochromatin is a real, specific action on chromatin, and the same action that releases a silenced ribosomal gene releases whatever else is silenced beside it. Nothing has looked at what else comes off in any system over any period, and 0 human safety studies exist at any dose.
Livagen — interference & stacking
Predicted from mechanism, not from an interaction study. How mechanism-predicted claims are made →
What Livagen moves on your bloodwork
Expected direction, not a measured one.
- Comprehensive Metabolic Panel (CMP) — ◆ worth watching
These are short peptide fragments given in microgram amounts and there is no mechanism predicting a specific marker shift. Listing markers here would be padding.
What to do: Test the organ system the bioregulator is aimed at, not a generic panel — that is the only measurement that would tell you anything.
The evidence base here is almost entirely one research group's, largely in Russian, and rarely replicated independently. That is the single most important thing to know before running a course, and it is more useful than any interaction list.
- How to work up to it, and when not to
- When to take it, and why that window
- Cycle length
- Time off between cycles
- Fasted or fed, and when in the day
- Needle gauge and injection site
- Coach Cam's personal notes
- Which compounds push the same lever, and why the dose adds up faster than people count
- What blunts it — the stacks that waste your money
- What compounds the risk, so a side effect arrives sooner than any one of them suggests
- Coach Cam's read on running it alongside the rest of your protocol
Everything above is free and stays free. Skool is where it becomes a plan — Livagen in an order, with the rest of what you're running.
Unlock in Skool — $10/mo →Bloodwork to run alongside Livagen
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| hs-CRP (High-Sensitivity C-Reactive Protein) | Chronic low-grade inflammation is the process most of these target |
| ApoB (Apolipoprotein B) | Counts the particles that actually cause plaque, unlike LDL-C |
| HbA1c (Hemoglobin A1c) | Glycation, which is the other half of the ageing story |
| Comprehensive Metabolic Panel (CMP) | Liver and kidney — the two organs that clear everything you take |
| Complete Blood Count (CBC) with Differential | The cheapest broad screen there is |
The Longevity Baseline panel covers these in one order — 13 markers, $219.10 with the discount applied.
Check results you already have → · All 103 markers A–Z
Livagen — frequently asked questions
What is the amino acid sequence of Livagen?
Livagen is Lys-Glu-Asp-Ala — 4 residues, 461.5 g/mol, isoelectric point 4.18. Those figures are computed from the sequence rather than quoted.
Can a peptide that short really bind DNA?
Not the way a transcription factor does. A zinc finger needs about 30 residues to read three base pairs. When Khavinson's group docked all 400 dipeptides against DNA, the vast majority could not bind double-stranded DNA at all. The claim is a computational prediction supported by gene-expression readouts in cells, not a measured binding event.
Is there a human trial of Livagen?
Nothing is indexed under the trade name Livagen; the peptide itself has one human-cell paper under its own name.
What should I measure if I run Livagen?
Before and after, not after alone. The falsifiability section on this page names the specific markers, the direction each should move and the timescale — and says what a null result would rule out.
References & further reading
- Khavinson VKh, Lezhava TA, Monaselidze JG, Dzhokhadze TA, Dvalishvili NA, Bablishvili NK, Ryadnova IYu — Effects of Livagen Peptide on Chromatin Activation in Lymphocytes from Old People · Bulletin of Experimental Biology and Medicine 2002;134(4):389–392 · PMID 12533768
- Khavinson VKh, Popovich IG, Linkova NS, Mironova ES, Ilina AR — Peptide Regulation of Gene Expression: A Systematic Review · Molecules 2021;26(22):7053 · PMID 34834147
- Khavinson V, Linkova N, Kozhevnikova E, Dyatlova A, Petukhov M — Transport of Biologically Active Ultrashort Peptides Using POT and LAT Carriers · International Journal of Molecular Sciences 2022;23(14):7733 · PMID 35887081
Livagen inside a finished plan
One arm of 2 Protocol Blueprints, free to read in full.
What Livagen is used for
Livagen appears under 2 goals in the goal router.
Related Longevity & Bioregulators compounds
Where this goes next
Livagen is the liver, kidney & gut arm of this plan. The page above is the free breakdown of one compound; the plan it belongs to — the dosing, the order to correct things in, the week-by-week schedule and what to retest — is a lesson inside Skool.